Holdings
Superstring Capital Management LP
As of Jun 30, 2026, Superstring Capital Management LP reported 29 positions worth US$144M. Largest: Cogent Biosciences, Inc., Axsome Therapeutics, Inc. and Genmab A/s. What it bought and sold, with each filing.
| Company | Shares | Value as reported | Change | As of |
|---|---|---|---|---|
| Cogent Biosciences, Inc. | 343K | US$13.3M | +118K | Jun 30, 2026 |
| Axsome Therapeutics, Inc. | 53,916 | US$13.2M | +42,699 | Jun 30, 2026 |
| Genmab A/s | 431K | US$11.8M | +234K | Jun 30, 2026 |
| Celldex Therapeutics, Inc. | 288K | US$10.7M | +108K | Jun 30, 2026 |
| Trevi Therapeutics, Inc. | 524K | US$9.78M | +273K | Jun 30, 2026 |
| Revolution Medicines, Inc. | 51,053 | US$9.56M | new | Jun 30, 2026 |
| Definium Therapeutics, Inc. | 188K | US$8.86M | −163K | Jun 30, 2026 |
| Vir Biotechnology, Inc. | 854K | US$8.7M | +123K | Jun 30, 2026 |
| Immunovant, Inc. | 208K | US$8.03M | −149K | Jun 30, 2026 |
| Climb Bio, Inc. | 521K | US$6.79M | +322K | Jun 30, 2026 |